Cometriq

Exelixis Has Announced The Availability of Cometriq (Cabozantinib)
Jan 29, 2013
Exelixis has announced the availability of Cometriq (cabozantinib), indicated for medullary thyroid cancer (MTC), in the US. Diplomat Specialty Pharmacy is distributing the product across the US. Cometriq that is developed to inhibit ...

Tags: Exelixis, Cometriq, tyrosine kinases